"what's so special about the dimx asset that make you think FDA...

"what's so special about the dimx asset that make you think FDA will give them free pass to accelerated? I just don't see it"

What you 'see' or 'don't see' is no more relevant than what anyone else here sees.

What is different about your position is the hubris in believing that the trial will be a failure before the event. An anonymous keyboard warrior believing they have better insights than all the PhD's in the Company their Clinical Advisory Board and Advanz Pharma.

I don't yet believe that DXB-200 IS special - as you are inferring. But I do believe it is potentially special (for multiple reasons) and that is why I recently invested.

Whether or not that potential is realised is something that neither you or I can yet know. But the Mar 2024 progress point will give strong clues to what may eventuate at the point - when 144 patients have been treated for 35 weeks - when accelerated marketing becomes a possibility.

Why you think you can second-guess this is beyond me. Arrogance? Compulsive need to acquire cheap shares?